Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics

Y Duan, K Gong, S Xu, F Zhang, X Meng… - Signal Transduction and …, 2022 - nature.com
Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

R Ross, IJ Neeland, S Yamashita, I Shai… - Nature Reviews …, 2020 - nature.com
Despite decades of unequivocal evidence that waist circumference provides both
independent and additive information to BMI for predicting morbidity and risk of death, this …

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus …

HN Ginsberg, CJ Packard, MJ Chapman… - European heart …, 2021 - academic.oup.com
Recent advances in human genetics, together with a large body of epidemiologic,
preclinical, and clinical trial results, provide strong support for a causal association between …

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

SJ Nicholls, M Ditmarsch, JJ Kastelein, SP Rigby… - Nature medicine, 2022 - nature.com
Global guidelines for the management of high-cardiovascular-risk patients include
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …

High-density lipoprotein revisited: biological functions and clinical relevance

A von Eckardstein, BG Nordestgaard… - European heart …, 2023 - academic.oup.com
Previous interest in high-density lipoproteins (HDLs) focused on their possible protective
role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and …

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target

J Behbodikhah, S Ahmed, A Elyasi, LJ Kasselman… - Metabolites, 2021 - mdpi.com
Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two
major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron …

Heart disease and stroke statistics—2019 update: a report from the American Heart Association

EJ Benjamin, P Muntner, A Alonso, MS Bittencourt… - Circulation, 2019 - Am Heart Assoc
Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …

HDL in the 21st century: a multifunctional roadmap for future HDL research

A Rohatgi, M Westerterp, A Von Eckardstein… - Circulation, 2021 - Am Heart Assoc
Low high-density lipoprotein cholesterol (HDL-C) characterizes an atherogenic dyslipidemia
that reflects adverse lifestyle choices, impaired metabolism, and increased cardiovascular …

Anabolic–androgenic steroids: How do they work and what are the risks?

P Bond, DL Smit, W de Ronde - Frontiers in Endocrinology, 2022 - frontiersin.org
Anabolic–androgenic steroids (AAS) are a class of hormones that are widely abused for
their muscle-building and strength-increasing properties in high, nontherapeutic, dosages …